NCT04379635 2026-03-18
Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)
BeOne Medicines
Phase 3 Active not recruiting
Clinical Trials
82 trialsNCT05635708 2026-03-18
A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer
BeOne Medicines
Phase 2 Active not recruiting
NCT06585488 2026-03-18
A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification
BeOne Medicines
Phase 1 Recruiting
NCT07468071 2026-03-12
KontRASt-R
Novartis
Phase 1/2 Not yet recruiting
NCT07120282 2026-03-09
Study to Evaluate the Efficacy and Safety of Adjuvant Tislelizumab in High-Risk Stage I NSCLC
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT07432984 2026-02-25
FMT-LUNG
Samsung Medical Center
Phase 2 Not yet recruiting
NCT07416474 2026-02-20
RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)
RemeGen Co., Ltd.
Phase 3 Not yet recruiting
NCT05577702 2026-02-09
Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer
BeOne Medicines
Phase 2 Completed
NCT07383116 2026-02-03
Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Tislelizumab Combined With Chemotherapy as First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer
Shanghai Huaota Biopharmaceutical Co., Ltd.
Phase 3 Not yet recruiting
NCT07131319 2026-02-02
SFRT+Tislelizumab+Platinum Chemotherapy for Unresectable Stage III NSCLC
Second Affiliated Hospital of Nanchang University
Phase 2/3 Recruiting
NCT05651022 2026-01-13
Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors
Indaptus Therapeutics, Inc
Phase 1/2 Active not recruiting
NCT07330037 2026-01-09
TALENT Study: Phase II Trial of Adjuvant L-TIL Plus Tislelizumab in Resectable NSCLC Without pCR After Neoadjuvant Chemoimmunotherapy
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Recruiting
NCT07320105 2026-01-06
Postoperative Radiotherapy for Postoperative N2 Metastases of NSCLC in the Immunotherapy Era (Phase II)
Fujian Cancer Hospital
Phase 4 Recruiting
NCT06877299 2026-01-02
Low-Dose Radiation + SBRT + Tislelizumab Plus Platinum-based Chemotherapy in Stage â…¡A-â…¢B Non-small Cell Lung Cancer
Sichuan University
Phase 2 Recruiting
NCT07264647 2025-12-04
Neoadjuvant Chemo-immunotherapy for Stage III PD-L1 Positive Non-Small Cell Lung Cancer (NSCLC)
Fondazione Ricerca Traslazionale
Phase 2 Recruiting
NCT05238883 2025-11-21
A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors
HiFiBiO Therapeutics
Phase 1 Active not recruiting
NCT05789069 2025-11-21
A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors
HiFiBiO Therapeutics
Phase 1 Active not recruiting
NCT07170995 2025-11-18
Phase III Study of SHR-8068 Combined With Adebrelimab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3 Recruiting
NCT06139419 2025-11-17
The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolidation for Locally Advanced NSCLC
Sun Yat-sen University
Phase 2 Active not recruiting
NCT06745908 2025-10-21
ResQ201A: Clinical Trial Of N-803 Plus TISLELIZUMAB And DOCETAXEL Versus DOCETAXEL Monotherapy In Participants With Advanced Or Metastatic Non-Small Cell Lung Cancer
ImmunityBio, Inc.
Phase 3 Recruiting
NCT03744468 2025-10-02
Study of BGB-A425 and LBL-007 in Combination With Tislelizumab in Advanced Solid Tumors
BeiGene
Phase 1/2 Completed
NCT06838208 2025-09-24
Tislelizumab Combined With Chemotherapy and Relayed Radiotherapy in First-line Treatment of ES-SCLC
Anhui Provincial Cancer Hospital
Phase 2 Recruiting
NCT05014815 2025-09-16
Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer
BeiGene
Phase 2 Completed
NCT07086456 2025-07-25
Combination of Concurrent Chemoradiotherapy With Surufatinib and Tislelizumab in Patients With Locally Advanced Non-Small Cell Lung Cancer
Sun Yat-sen University
Phase 2 Recruiting
NCT06379087 2025-07-10
Radiation Therapy Followed by Tislelizumab and Anlotinib Aeoadjuvant/Adjuvant Therapy for Stage II-IIIA NSCLC
Zhejiang Cancer Hospital
Phase 2 Recruiting
NCT06977828 2025-06-29
A Prospective, Single-arm, Phase II Clinical Study of Tislelizumab Combined With Anlotinib and Platinum-based Doublet Perioperative Therapy for Resectable Stage II-IIIB Driver Gene-negative NSCLC
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Not yet recruiting
NCT04746924 2025-06-24
A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer
BeiGene
Phase 3 Active not recruiting
NCT05319574 2025-06-12
SACTION01
Sun Yat-sen University
Phase 2 Active not recruiting
NCT06969612 2025-06-06
A Study on the Efficacy and Safety of Golidocitinib Combined With Tislelizumab and Chemotherapy as First-line Treatment for Advanced NSCLC
Peking University Cancer Hospital & Institute
Phase 1 Recruiting
NCT06598527 2025-05-29
SACTION2401
Sun Yat-sen University
Phase 3 Recruiting
NCT06659042 2025-05-18
Perioperative Tislelizumab for Resectable II-IIIB(N2) KRAS-mutated Nonsquamous Non-small Cell Lung Cancer
Shanghai Chest Hospital
Phase 2 Recruiting
NCT04579757 2025-05-08
Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors
Hutchmed
Phase 1/2 Terminated
NCT04261439 2025-05-06
A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab
Novartis
Phase 1 Terminated
NCT05840016 2025-05-02
AK112 in Combination With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer
Akeso
Phase 3 Active not recruiting
NCT06030258 2025-04-30
IN10018 Combination Therapy in Treatment-naïve ES-SCLC
InxMed (Shanghai) Co., Ltd.
Phase 1/2 Recruiting
NCT06951841 2025-04-30
Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction
China Medical University, China
Phase 4 Not yet recruiting
NCT06939127 2025-04-22
Cryoablation Combined With Tislelizumab and Chemotherapy as Neoadjuvant and Adjuvant Therapy in Resectable Stage II-IIIB NSCLC
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Recruiting
NCT06897579 2025-04-11
Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2 Recruiting
NCT06416410 2025-04-04
JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation
Allist Pharmaceuticals, Inc.
Phase 3 Recruiting
NCT06883552 2025-03-19
An Open-label, Single-arm Clinical Study of Stapokibart Injection in Combination with Tislelizumab Injection in Patients with Non-Small Cell Lung Cancer
Sichuan University
Phase 2 Not yet recruiting
NCT05058560 2025-03-13
Tislelizumab in Addition to BACE in Patients with NSCLC
The First Affiliated Hospital of Zhengzhou University
Phase 2 Completed
NCT06868732 2025-03-11
Evaluation of JSKN016 Combination Therapy in Subjects with NSCLC
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase 1 Not yet recruiting
NCT04005716 2025-02-28
Study of Platinum Plus Etoposide With or Without Tislelizumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer
BeiGene
Phase 3 Completed
NCT03358875 2025-02-10
RATIONALE-303
BeiGene
Phase 3 Completed
NCT03663205 2025-02-04
A Study Evaluating the Efficacy and Safety of Tislelizumab Versus Chemotherapy in Advanced Non-Squamous Non-small Cell Lung Cancer
BeiGene
Phase 3 Completed
NCT05431270 2025-01-31
Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 MAb, Administered Alone and in Combination with a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)
Phanes Therapeutics
Phase 1/2 Recruiting
NCT06793228 2025-01-27
Nanocrystalline Megestrol + Immunochemo As 1st-Line for ES-SCLC Cachexia
Henan Cancer Hospital
Phase 2 Not yet recruiting
NCT06749860 2024-12-27
Disitamab Vedotin in Combination with Tislelizumab and Bevacizumab in a Phase II Clinical Study of Locally Advanced or Metastatic Non-small Cell Lung Cancer with HER2 Mutation/amplification/expression
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2 Recruiting
NCT06749886 2024-12-27
An Exploratory Study of Tislelizumab in Combination with Chemotherapy in Immuno-experienced Patients with EGFR/ALK/ROS1-negative Advanced NSCLC in the Second-line Setting
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2 Recruiting
NCT06704620 2024-12-16
Study of Tislelizumab and Platinum-based Chemotherapy Combination With H1 Receptor Antagonist（Diphenhydramine）in Advanced and Metastatic Non-Small Cell Lung Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 3 Not yet recruiting